How to Submit a Clinical Trial Application in the EU
Navigate a single submission that is assessed jointly by every member state you selected.
What a how-to is not
A how-to is SPEQ’s practitioner method, not a procedure. It does not replace your own SOP, it is not a validated approach, and the judgement calls in it belong to your quality unit.
The EU moved from national applications under a directive to a single application assessed through one portal, and the transition period for legacy trials closed in January 2025. The architecture is what practitioners have to internalise: the dossier splits into a part assessed jointly across all concerned member states and a part assessed nationally, and the clock stops in ways that reward a complete first submission.
- 1
Choose the concerned member states and the reporting member state
You select where the trial will run and propose which state coordinates the joint assessment. That choice shapes the whole timetable, because the coordinating state drives the joint part and consolidates the questions from the others.
- 2
Split the dossier correctly between the joint and national parts
Scientific and product content — protocol, investigator brochure, manufacturing and import, labelling — is assessed jointly and must be identical for every state. Ethics, consent, recruitment arrangements, data protection and site suitability are assessed nationally and may legitimately differ. Content filed in the wrong part is the most common cause of an early validation failure.
- 3
Prepare for validation before assessment begins
The application is first checked for completeness, and only then assessed. A missing document at this stage costs a cycle rather than a comment, so treat the completeness check as the first review rather than an administrative formality.
- 4
Answer requests for information inside the window given
The clock is suspended while you respond and resumes when you do, and the window is fixed. An unanswered request lapses the application rather than deferring it, so partial answers filed on time beat complete answers filed late.
- 5
Expect one decision per member state on a jointly assessed conclusion
The joint part produces a single conclusion; each state then issues its own decision covering both parts. A state may disagree with the joint conclusion only on defined grounds, so a joint objection is effectively decisive and is where your response effort belongs.
- 6
Plan substantial modifications and results reporting into the same portal
Amendments, the addition of member states, and results submission all run through the same route on defined timetables. Teams that treat the initial authorisation as the end of the portal work discover the reporting obligations late, and lateness there is visible publicly.
- !Ethics or site-suitability content filed in the jointly assessed part, or scientific content varied between states.
- !Validation treated as administrative, so an incomplete dossier costs a full cycle rather than a comment.
- !A request for information answered after the fixed window, lapsing an application that was otherwise sound.
- !Results and modification obligations discovered after authorisation, when the timetable has already started.
How to Submit a Clinical Trial Application in the EU: frequently asked questions
Common questions on submit a clinical trial application in the eu.
What is the difference between the jointly assessed and nationally assessed parts?
The joint part covers the science and the product — protocol, brochure, manufacturing, labelling — and must be identical across every concerned member state. The national part covers ethics, informed consent arrangements, recruitment, data protection and site suitability, which are properly matters for each state. Misfiling between them is a validation failure, not a comment.
What happens if a member state disagrees with the joint conclusion?
It may only disagree on defined grounds, and it then issues its own negative decision for its territory. In practice this means a joint objection has to be answered on its merits — there is no route to authorisation in one state by argument that the joint conclusion should not apply there.
What happened to trials authorised under the old directive?
They had to be transitioned to the regulation and the portal during a defined transition period that closed in January 2025. There is no longer a parallel national route for a trial with an active EU site, which is why legacy processes and templates should have been retired rather than kept as an alternative.